Tobira Therapeutics Inc., a Manalapan, NJ-based biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, has completed a $31m Series B financing.
The round was led by new investor Novo A/S, with participation from original funders, Domain Associates, L.L.C., Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.
Proceeds from the financing will be used to advance the clinical program for its lead compound TBR-652, a dual-action CCR5/CCR2 antagonist, in CCR5-tropic, treatment-naïve HIV patients.
The company announced plans for a Phase IIb clinical trial, based on completion of its Phase IIa proof-of-concept study, which earlier this year demonstrated potent antiviral and anti-inflammatory activity in treatment-experienced HIV patients.
Founded in 2006 by Eckard Weber, M.D., a partner at Domain Associates, Tobira Therapeutics has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.